Marinus Pharmaceuticals Inc.

Address: 5 Radnor Corporate Center Suite 500

Sponsor Overview

assignment

Specializations

Epilepsy and Seizure Disorders

Marinus Pharmaceuticals Inc. focuses on clinical research in difficult-to-treat epilepsy conditions, with particular attention to seizure control in patients whose symptoms remain active despite standard treatment.

Refractory Status Epilepticus
Adjunctive anti-seizure therapy
Intravenous treatment for acute seizure management

The sponsor’s work in this area centers on therapeutic options for severe seizure emergencies and ongoing seizure burden in clinical settings requiring intensive neurological care.

Tuberous Sclerosis Complex-Related Epilepsy

Another key area of interest is Tuberous Sclerosis Complex-associated epilepsy, with research aimed at seizure management across both pediatric and adult populations.

TSC-related epilepsy
Long-term seizure control
Children and adults with chronic epilepsy

This therapeutic focus reflects an emphasis on managing persistent seizures linked to a complex neurodevelopmental disorder.

Neurology and Central Nervous System Therapeutics

The clinical portfolio is positioned within neurology, especially disorders involving abnormal brain excitability and urgent seizure intervention.

Central nervous system disorders
Seizure emergency treatment
Adjunctive therapy in neurological disease

Research activity in this domain supports development of treatments for neurological conditions where seizure suppression is a primary clinical goal.

Pediatric and Adult Neurological Care

Marinus Pharmaceuticals Inc. also shows interest in therapies that address epilepsy across age groups, including both pediatric and adult patients.

Age-inclusive epilepsy care
Chronic seizure disorders
Supportive treatment alongside standard anti-epileptic drugs

This area of research spans long-term management needs in patients living with complex seizure disorders over different stages of life.

Trial Name	Country	Status
A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus	Austria Belgium Croatia Czechia Denmark Finland France Germany Hungary Italy Lithuania Poland Slovakia Spain	Not Recruiting
Phase 3 Open-label Study of Adjunctive Ganaxolone in Tuberous Sclerosis Complex-Related Epilepsy in Pediatric and Adult Populations	Belgium France Germany Italy Spain	Not Recruiting